8-K

   As filed with the Securities and Exchange Commission on November 13, 2000

================================================================================


                      SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C. 20549

                                   FORM 8-K

                                CURRENT REPORT
                    Pursuant to Section 13 or 15(d) of the
                      Securities and Exchange Act of 1934

      Date of Report (Date of earliest event reported):  November 8, 2000

                                  AMGEN INC.
            (Exact name of Registrant as specified in its charter)

           Delaware                                           95-3540776
(State or other jurisdiction of        000-12477          (I.R.S. Employer
incorporation or organization)    (Commission File No.)   Identification No.)

                              __________________

                            One Amgen Center Drive
                     Thousand Oaks, California 91320-1799
          (Address of Principal Executive Offices including Zip Code)

                                (805) 447-1000
             (Registrant's Telephone Number, Including Area Code)


Item 5.  OTHER EVENTS AND REGULATION FD DISCLOSURE

     On November 8, 2000, the Registrant publicly disseminated a press release
updating the investment community on the Registrant's business and providing
certain financial guidance.

     The foregoing description is qualified in its entirety by reference to the
following document, which is incorporated herein by reference: the Registrant's
Press Release dated November 8, 2000, a copy of which is attached hereto as
Exhibit 99.1.

Item 7.  FINANCIAL STATEMENTS AND EXHIBITS

       (a)  Financial Statements.

            Not applicable.

       (b)  Pro Forma Financial Information.

            Not applicable.

       (c)  Exhibits.

            99.1  Registrant's Press Release dated November 8, 2000.


                                  SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

Date: November 13, 2000                  AMGEN INC.

                                        By:     /s/ Kathryn E. Falberg
                                                _______________________________
                                        Name:   Kathryn E. Falberg
                                        Title:  Senior Vice President, Finance
                                                and Corporate Development and
                                                Chief Financial Officer

EX-99.1

                                                                    EXHIBIT 99.1

                    AMGEN FORECASTS ACCELERATION OF SALES
                      AND EARNINGS GROWTH FOR 2001-2005
                            DRIVEN BY NEW PRODUCTS

         Announces Clinical Trial Advances on ARANESP/TM/, SD/01 & KGF

FOR IMMEDIATE RELEASE

NEW YORK, November 8, 2000 -- Amgen (NASDAQ:AMGN) today outlined its strategy
for delivering accelerated sales and earnings per share growth for the period
2001-2005, driven by ARANESP/TM/ (darbepoetin alfa), which is currently under
regulatory review, and other new products.   Earnings growth will accelerate in
2001 and beyond with sales expected to reach between $8 billion and $9 billion
by 2005, Chief Executive Officer and President Kevin Sharer told financial
analysts and major shareholders at the Company's business review meeting.

"These are exciting times for Amgen.  ARANESP is a huge opportunity, and Amgen
is well prepared to capitalize on it.  The worldwide anemia treatment market,
currently estimated at $5 billion, is projected to double over the next five
years.  We expect to introduce five or more new products by 2005 which will
enable Amgen to participate in new markets with an estimated value of $13
billion by 2005 that Amgen does not compete in today," Mr. Sharer said.

Mr. Sharer, who was elected CEO earlier this year, outlined the strategies he
said must be successfully employed to deliver this accelerated earnings per
share growth:

 .  Focus R&D on four therapeutic areas using proteins, antibodies and small
   molecules
 .  Invest in R&D at an industry leading percentage of sales
 .  Aggressively build and advance the pipeline
 .  Invest aggressively to support new product launches
 .  Attract and retain the best people
 .  Balance near-term earnings with investment for long-term growth.

                                    - MORE -


AMGEN FORECASTS ACCELERATION OF SALES AND EARNINGS GROWTH FOR 2001-2005 DRIVEN
BY NEW PRODUCTS
Page 2

Stan Benson, Senior Vice President, Sales and Marketing, outlined the potential
for ARANESP in the nephrology and oncology markets, as well as other future
indications.  ARANESP may represent a new standard of care for treating anemia
in chronic kidney disease and other settings, he said.

"The launch of ARANESP represents a major advance for patients with anemia.  In
the United States, Amgen intends to focus initially on treating the anemia
associated with chronic renal insufficiency (CRI), a precursor to chronic renal
failure requiring dialysis.  CRI has been called a `hidden epidemic'," Mr.
Benson said.  In Europe, both the CRI and dialysis markets will be new markets
for Amgen, Mr. Benson added.

Amgen intends to leverage its strong presence in nephrology to fully develop the
U.S. and European CRI markets.  The number of CRI patients at risk is large.  Of
the 1 million Americans with progressive CRI, about 350,000 suffer from anemia
that requires treatment.  However, just 90,000 of these people with anemia are
actually treated.

In Europe, where Amgen does not market EPOGEN/R/ (Epoetin alfa), and where most
dialysis patients receive anemia treatments through subcutaneous administration,
the opportunities for ARANESP are compelling.  ARANESP will enjoy an advantage
of less frequent dosing over current therapies, Mr. Benson added.

Amgen is currently pursuing oncology as its next indication for ARANESP.  The
oncology market for anemia treatment is also under-penetrated, despite the fact
that sales of anemia treatments in this setting are approaching $2 billion.  It
is thought that no more than 20 percent of anemic cancer patients are currently
being treated, Mr. Benson said.


Prospects for Additional New Products Outlined
- ----------------------------------------------
The Company also outlined the potential of its other near-term product
candidates.

In the rheumatoid arthritis market, Amgen's IL-1ra (anakinra) has a unique
biological pathway with well-characterized effects on disease progression, Mr.
Benson said.  The Company has stated previously that it may receive a response
to its FDA license application as early as the second half of 2001.

                                    - MORE -


AMGEN FORECASTS ACCELERATION OF SALES AND EARNINGS GROWTH FOR 2001-2005 DRIVEN
BY NEW PRODUCTS
Page 3

Upon regulatory approval, Abarelix will enter a competitive prostate cancer
market with unique features.  In clinical trials to date, Abarelix, with its
novel mechanism of action, has been shown to block the hormones that fuel the
growth of cancer cells and rapidly reduce the levels of testosterone and other
hormones involved in the growth of the cancer.  Abarelix accomplishes this
without the testosterone surge seen with currently available products, Mr.
Benson said.

In his review of Amgen's NEUPOGEN/R/ (Filgrastim) and EPOGEN businesses, Mr.
Benson reported that sales of NEUPOGEN continue to grow in curative treatments
but that there is a significant challenge to NEUPOGEN growth in the non-curative
chemotherapy setting. Amgen is focused on expanding NEUPOGEN's positioning to
help patients avoid serious chemotherapy-induced side effects requiring
hospitalization.

Sales of EPOGEN are continuing to grow, largely due to the approximately 6 to 7
percent annual growth in the number of patients.  EPOGEN sales may also benefit
through Amgen's efforts to improve the quality and duration of patients lives by
working with dialysis providers to move more patients into the target hematocrit
range, Mr. Benson said.

R&D Investment Yielding Pipeline Progress
- -----------------------------------------
Dr. George Morstyn, Senior Vice President, Development, and Chief Medical
Officer, highlighted several significant developments in Amgen's product
pipeline.

Amgen announced that the first pivotal clinical trial of ARANESP in oncology is
nearing completion.  The Company also reported that in dose-finding studies,
injections of ARANESP once every three weeks appear to have efficacy equal to
that of rHuEPO administered three times per week.  Under current labeling,
cancer patients receive injections of rHuEPO three times a week.

Dr. Morstyn announced that the pivotal phase 3 trials of SD/01, the long-acting
form of NEUPOGEN were successful as supportive therapy in women with breast
cancer.  Upon completion of the follow-up phase, Amgen expects to file a license
application for SD/01 with the FDA in the first half of 2001.

                                    - MORE -


AMGEN FORECASTS ACCELERATION OF SALES AND EARNINGS GROWTH FOR 2001-2005 DRIVEN
BY NEW PRODUCTS
Page 4

Dr. Morstyn also disclosed that Amgen plans to begin phase 3 clinical trials of
KGF (keratinocyte growth factor) in the first quarter of 2001.  KGF is a
recombinant form of a naturally-occurring epithelial tissue growth factor which
stimulates the growth and development of cells that comprise the lining of the
surface of the gastrointestinal tract.  KGF appears to offer benefit for
patients who experience mucositis following chemotherapy.

Amgen said that its pipeline continues to advance and deliver important new
therapeutics for the future.  The Company expects that as many as three new
products may be approved in 2001, including ARANESP in the first half of the
year.  The Company further expects to initiate two phase 3 trials in 2001 and to
begin up to three phase 1 clinical trials.

Company Provides Financial Guidance for 2001-2005
- -------------------------------------------------
Kate Falberg, Senior Vice President, Finance and Corporate Development, and
Chief Financial Officer, provided an in-depth discussion of Amgen's financial
expectations for 2001.  Total product sales are expected to grow in the mid to
high teens in 2001, and earnings per share are expected to grow in the mid
teens, excluding non-recurring items.

Combined sales growth in 2001 of ARANESP and EPOGEN is expected to be in the
high teens to low twenties, and sales growth of NEUPOGEN is expected to be in
the high single digits.

Cost of goods is expected to be in the range of 11.5 percent to 12.5 percent as
a percent of sales.  R&D and SG&A (Sales, General and Administrative) expenses
are each estimated to be in the range of 25 percent to 27 percent of sales.  The
tax rate is expected to be approximately 34 percent in 2001.

Reflecting optimism about Amgen's future, Ms. Falberg spoke of accelerated sales
and earnings growth for the period 2001-2005.  The five-year, compound average
growth rate is expected to be in the low twenties for both sales and earnings
per share.

This news release contains forward-looking statements that involve significant
risks and uncertainties, including those discussed below and more fully
described in the Securities and Exchange Commission reports filed by Amgen,
including our most recent Form 10-Q.  Amgen conducts research in the
biotechnology/pharmaceutical field where movement from concept to product is
uncertain; consequently, there can be no guarantee that any particular product
candidate will be successful and become a commercial product.
                                    - MORE -


AMGEN FORECASTS ACCELERATION OF SALES AND EARNINGS GROWTH FOR 2001-2005 DRIVEN
BY NEW PRODUCTS
Page 5

Furthermore, our research, testing, pricing, marketing and other operations are
subject to extensive regulation by domestic and foreign government regulatory
authorities.  In addition, sales of our products are affected by reimbursement
policies imposed by third party payors, including governments, private insurance
plans and managed care providers. These government regulations and reimbursement
policies may affect the development, usage and pricing of our products.

In addition, while we routinely obtain patents for our products and technology,
the protection offered by our patents and patent applications may be challenged,
invalidated or circumvented by our competitors.

Because forward-looking statements involve risks and uncertainties, actual
results may differ materially from current results expected by Amgen.  Amgen is
providing this information as of November 8, 2000, and does not plan to update
this information until its next earnings press release and expressly disclaims
any duty to update information contained in this press release.

Amgen is a global biotechnology company that discovers, develops, manufactures
and markets cost-effective human therapeutics based on advances in cellular and
molecular biology.


CONTACT:    Amgen, Thousand Oaks
            David Kaye, 805/447-6692 (media)
            Cary Rosansky, 805/447-4634 (investors)

                                     # # #

EDITOR'S NOTE:  An electronic version of this news release may be accessed via
our web site at www.Amgen.com.  Visit the Corporate Center and click on Amgen
News.  Journalists and media representatives may sign up to receive all news
releases electronically at time of announcement by filling out a short form in
the Amgen News section of the web site.